TEVA, US8816242098

Simply Wall St raises fair value for Teva stock to USD 45.30

Published on 10/09/2026 at 13:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 4.14 billion, down 1.00 percent year over year. Teva stock last stood at USD 39.25 versus USD 40.79 high.

Key points in brief

Simply Wall St raised its fair value estimate for Teva from USD 42.00 to USD 45.30 on October 8, 2026.
Teva reported USD 4.14 billion in second-quarter 2026 revenue, down 1.00 percent year over year.
Teva stock was last at USD 39.25 on October 8, 2026, below its USD 40.79 52-week high.
Teva is scheduled to report third-quarter 2026 results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Simply Wall St raised its fair value estimate for Teva Pharmaceutical Industries from USD 42.00 to USD 45.30 on October 8, 2026, giving Teva stock a fresh valuation reference. The estimate reflects expected contributions from AUSTEDO, AJOVY, UZEDY and the broader neuroscience portfolio.

Three milestones shape the story

On July 29, 2026, Teva reported second-quarter revenue of USD 4.14 billion, down 1.00 percent from the second quarter of 2025. According to Trivano, Teva also reported a GAAP loss per share of USD 0.49, primarily reflecting USD 726 million of expenses tied to the Emalex acquisition.

On September 14, 2026, Teva began direct trading of its ordinary shares on the New York Stock Exchange. The company said the one-for-one exchange replaced its American Depositary Share program, while its ordinary shares continued trading on the Tel Aviv Stock Exchange, according to Trivano.

On October 2, 2026, Teva presented new ecopipam data in pediatric Tourette syndrome. Finanzen reported that 69.80 percent of 292 patients achieved a clinically meaningful reduction in tic severity within eight weeks.

What does the valuation imply?

The USD 45.30 fair value estimate stands 15.54 percent above the USD 39.25 last price. That comparison gives the market a numerical measure for the valuation debate, while the latest operating figures show a split picture: innovative brands are expanding, but generic-drug pressure and acquisition costs weighed on reported earnings.

Next results arrive November 3

Teva is scheduled to report third-quarter 2026 results on November 3, 2026, at 7:00 a.m. ET, according to Simply Wall St. That report will test whether portfolio growth can offset the second-quarter revenue decline and the cost burden from Emalex.

Teva stock stays below yearly high

Teva stock was last at USD 39.25 on the NYSE on October 8, 2026 at 4:00 p.m. ET, versus a previous close of USD 39.18 and a 52-week range of USD 18.83 to USD 40.79. Its market capitalization was USD 45.7 billion as of October 8, 2026.